

Radiotherapy treatment of human inflammatory diseases and conditions: Optimal dose

EJ Calabrese¹ , G Dhawan², R Kapoor³ and WJ Kozumbo⁴

Abstract

During the early part of the past century, hundreds of clinical studies involving more than 37,000 patients were conducted that showed radiotherapy (RT) to be a successful and safe alternative to drug therapy for the treatment of many diverse inflammatory conditions and diseases (e.g. tendonitis, bursitis, arthritis, and serious inflammatory lung conditions). Data from these studies were collected and analyzed with the intent of estimating an optimal dosing range for RT that would induce an efficacious treatment response. RT was reported to be frequently effective after only a single treatment, with a rapid (within 24 h) and often long-lasting (from months to years) relief from symptoms. Over a two-decade span from the 1920s to the 1940s, the therapeutic responses to a single RT treatment consistently improved as the dosing for multiple ailments decreased over time to between 30 roentgen (r) and 100 r. These findings are significant and in agreement with a number of contemporary reports from Germany where RT has been commonly and successfully employed in treating ailments with an inflammatory origin. A proposed mechanism by which RT mitigates inflammation and facilitates healing is via the polarization of macrophages to an anti-inflammatory or M2 phenotype.

Keywords

Radiotherapy, inflammation, macrophage polarization, hormesis, adaptive response, dose response

Introduction

Various environmental signals have been shown to elicit pleotropic effects in macrophages and to polarize them into one of two distinct phenotypes: (1) a pro-oxidative/pro-inflammatory M1 phenotype or (2) an anti-inflammatory M2 phenotype.¹ This observation spurred considerable interest in using environmental stimuli, such as diet, pharmaceuticals, and lifestyle factors (e.g. exercise), to modulate anti-inflammatory phenotypes and thereby reduce pro-inflammatory symptoms like pain and swelling. Relatively recently, this anti-inflammatory process was shown to be mediated largely by the polarization of macrophages toward an M2 phenotype.^{1–3}

Within this context, several studies have indicated that ionizing radiation induces macrophage polarization, with the capacity to polarize macrophages toward either M1 (pro-oxidative) or M2 (anti-inflammatory) phenotypes depending on the radiation dose.^{4,5} These observations are potentially significant since they help explain the dual capacity of ionizing

radiation to be effective in both treating inflammatory conditions (i.e. M2 mediated) and killing microbes and tumor cells (i.e. M1 mediated).

To identify the most effective range of dosing used in the radiotherapy (RT) of many ailments possessing significant inflammatory components, it was necessary to retrieve and reevaluate as much historical data as possible. Herein, RT studies are identified^{6–13} that were conducted on more than 37,000 patients in the

¹Department of Environmental Health Sciences, University of Massachusetts, Amherst, MA, USA

²Mass Venture Center, Research Compliance, University of Massachusetts, Hadley, MA, USA

³Saint Francis Hospital and Medical Center, Hartford, CT, USA

⁴Consultant, Baltimore, MD, USA

Corresponding author:

EJ Calabrese, Department of Environmental Health Sciences, University of Massachusetts, Morrill I, N344, Amherst, MA 01003, USA.

Email: edwardc@schoolph.umass.edu

Table 1. Human diseases/conditions successfully treated with radiotherapy.

	Number of subjects	Successful treatment (%)	Studies (N)	References
Arthritis	>5000	~ 85	Cumulative experience	Kahlmeter ¹⁴ and Kuhns and Morrison ¹⁵
Bronchial asthma	~ 4000	75–80	57	Calabrese et al. ¹²
Carbuncles	187	60–90	5	Calabrese ⁶
Cervical adenitis	893	75–90	11	Calabrese and Dhawan ¹⁰
Deafness	15,000	>95%; performed prior to age 15	Cumulative experience	Crowe and Baylor ²²
Furuncles	420	75–95	5	Calabrese ⁶
Gas gangrene	365	Mortality rate decreased from 40% to 10%	13	Calabrese and Dhawan ⁷
Otitis media/mastoides	564	~ 90	16	Calabrese and Dhawan ¹⁰
Pertussis	~ 2400	~ 80	22	Calabrese et al. ¹³
Pneumonia	863	80–85	18	Calabrese and Dhawan ⁸
Sinus infection	4492	75–90	16	Calabrese and Dhawan ⁹
Tendonitis/bursitis	3333	70–90	31	Calabrese and Dhawan ¹⁰
	37,517			

first part of the last century, ranging in time from about 1910 to the early 1950s. Each ailment had its own historical foundation as was described in prominent medical journals of the era. The strengths and limitations of the studies were assessed in each review publication according to the specific ailment, as cited above. In general, the clinical successes of RT were not only substantial for each type of ailment but also repeatedly confirmed by independent studies.

Despite differing from each other extensively in terms of etiology, symptomatology, and conventional therapy, all 13 ailments were resolved using the same treatment modality, RT (Tables 1 and 2). The remarkable success of RT in the treatment of multiple diverse ailments is likely related to the view that inflammation is a central feature of each ailment and that RT somehow counteracts the inflammatory process, affording protection and enabling repair of tissue. Since each of these ailments displays the central pathological feature of marked inflammation, it is not unreasonable to deduce that RT at the right dose can act as a potent anti-inflammatory agent.

Anti-inflammatory response: Mediated by macrophage polarization

A mechanistic understanding of how RT could enhance the healing and recovery of so many diverse ailments was not known in the early decades of the

20th century. Recent findings, however, have indicated that relatively low doses of X-rays/ γ -rays can induce the development of a highly integrated and systemic response involving the polarization of macrophages toward an anti-inflammatory M2-like phenotype.^{23–25} The polarization response of macrophages to physical stimuli, such as nonionizing radiation, represents a rather recent and novel observation. Chemical agents, on the other hand, have routinely been used as polarization stimuli and have therefore played a fundamental role in identifying typical biomolecular events involved in mediating an M2 as well as M1 polarization response in macrophages. The following events have been identified as being involved in mediating an M2 polarization response: decreases in nitric oxide levels and in inducible nitric oxide synthase, decreases in reactive oxygen species, increases in heme oxygenase, suppression of tumor necrosis factor α , increases in tumor growth factor β , and the activation of several transcription factors, including nuclear factor $\kappa\beta$ and activating factor protein 1. The fact that this chemically elicited biomolecular response is similar to the biomolecular response induced specifically by low-dose X-rays lends support to the idea that—like certain chemicals—RT mediates its anti-inflammatory effects via the polarization of macrophages toward an anti-inflammatory M2-like phenotype.¹

Table 2. Optimal radiotherapeutic dose range to treat human inflammatory conditions, injury, infectious disease, and other cases.

Clinical conditions	Optimal human dose range (total dose)	Comment	References
Arthritis	150–250 r	Similar optimal dose ranges were reported in mouse arthritic models—see table III, page 292, Calabrese and Calabrese ¹⁵ ; this exposure was given on a weekly basis. Depending on the patient the treatment could be limited to single treatment or repeated up to three times.	Trott ^{16,17}
Bronchial asthma	250 r—and possibly lower—see comment	Report on 1000 cases: 850 improved with 250 r total dose; the therapeutic dose decreased from the mid-1920s to the 1940s; in 1949 Leddy and Maytum were recommending further lowering the dose to 100 r or less; in their experience most patients required only one treatment and reported relief within 24 h.	Leddy and Maytum ¹⁸
Bursitis	100–150 r	Multiple independent studies (see table 2, page 1505); beneficial responses were reported over a broad dose response, depending on the subject, ranging from as low as 0.1 of the SED to multiples of this value, depending on the subject. According to Laltomus and Hinter ³¹ many patients were relieved of symptoms after the first 100 r treatment.	Calabrese et al. ¹¹
Cervical adenitis (massively swollen lymph nodes, neck area)	60 r	75–90% markedly improved/cured (see tables 5 and 6, page 550); dosing evolved to approximately 0.1 SED over two decades.	Calabrese and Dhawan ¹⁰
Carbuncles	35–50 r	See table 5, page 822; the initial optimal treatment in the 1920s was 0.5–0.75 SED, dropping to 0.1–0.2 a decade later.	Calabrese ⁶
Furuncles	35–50 r	See table 5, page 822; see explanation for carbuncles which is directly relevant for furuncles.	Calabrese ⁶
Gas gangrene	120–150 r	Based on Bowen, ⁴⁶ treatment given immediately after admitted to hospital.	Calabrese and Dhawan ⁷
Otitis media	~20–50 r	Very high rate of clinical (>90%) improvement; chronically affected patients tended to receive multiple treatments; treatment dose was reported as 0.10–0.20 SED. This dose (i.e. 20–50 r) was administered over the affected ear. ¹⁹ These figures are in general agreement with the 62 r dose of McLaurin. ²⁰	Calabrese and Dhawan ¹⁰
Mastoides	~70–75 r	Similar to findings with otitis media; dosing was reported to be approximately 0.25 SED; Lucinian ²¹ reported that 0.20 SED with a single dose was effective.	Calabrese and Dhawan ¹⁰
Pneumonia	50–125 r	The dosing was based initially on that used for the treatment of carbuncles.	Calabrese and Dhawan ⁸
Sinus infections	50–100 r	Effective in children and adults; therapeutic doses decreased markedly from the early 1930s to mid-1940s, from 900 r to 50–100 r. ^{14,15,22} Improvement with a single treatment occurred in 25–50% of patients, with some claiming cures. Extensive lead shielding employed.	Calabrese and Dhawan ⁹

(continued)

Table 2. (continued)

Clinical conditions	Optimal human dose range (total dose)	Comment	References
Tendonitis, shoulder	100–150 r	Based upon multiple independent studies; progressive decrease from 350–400 r to 100 r over two decades; see comment for bursitis.	Calabrese et al. ¹¹
Pertussis	37.5–50 r	Treatments were purposely low dose due to the young age of many patients; the dose was about 0.1 SED; the treatments were often a single dose but could be given up to three times for initially less responsive subjects.	Calabrese et al. ¹³




Figure 1. Effects of radiation dose on macrophage polarization. *Source:* Based in part on Calabrese et al.,¹ Genard et al.,⁵ and Pinto et al.⁶⁰

Results

Tables 1 and 2 indicate that RT, at a relatively narrow dose range of between 30 roentgen (r) and 150 r (0.3–1.5 Gy), was effective in treating a spectrum of inflammatory ailments (some with concomitant infectious components). The skin erythema (i.e. skin reddening) dose (SED) is an upper bound exposure point of reference and was used in the estimation and selection of most doses for all end points. The SED had long been established as a biological exposure standard to judge excessive exposure to ionizing radiation; it was a type of visual radiation badge. This

visual biomarker was used before Muller²⁶ who reported that X-rays could induce gene mutations in the fruit fly.²⁷ A detailed review of the historical foundations of the SED indicates that its recommended value of 350–500 r²⁸ varied to some extent during the 1920s and 1930s. The SED estimate could be affected by X-ray filtration techniques and multiple characteristics of the patient, such as age, gender, degree of skin pigmentation and vascularization, among other factors. This historical context indicates that the SED represents a value (and thus fractional values)⁶ possessing a fair degree of uncertainty and some inaccuracy, even though it was a widely recognized frame of

reference at the time. If safe and effective doses of RT were based on uncertain and inaccurate estimates of SED, it stands to reason that the optimal dosing range of RT, as reported in the historical literature, would also be less than accurate.

Another factor reducing confidence in the accuracy of the optimal dosing range for RT, as reported in the literature, was the progressive lowering of RT doses (fractions of the SED) that occurred over time, as clinical outcomes noticeably improved with the use of lower doses of RT. For example, in the 1920s, X-ray doses used in the treatment of carbuncles ranged from 0.5 to 0.75 SED (i.e. 175–375 r), dropping to 0.1 to 0.2 SED (i.e. 35–100 r) during the 1930s.⁶ Similarly, shoulder tendonitis was successfully treated with X-rays at 350–400 r in the 1930s,^{29,30} but by the late 1940s, the treatment dose had declined to 100 r.³¹ Furthermore, clinicians from one subgroup specialty learned from another, copying the more effective treatment protocol irrespective of the designated ailment. For example, in selecting an RT dose to treat pneumonia, clinicians were swayed by publications describing the successful treatment of carbuncles with X-rays.⁶

This array of different starting points, protocols, end points, and inter-clinician collaborations created a somewhat confusing clinical picture for this novel treatment modality, especially in the 1920s and early 1930s. However, from the 1930s to the mid-1940s, clinicians tended to select the most effective treatment protocols within disease categories, gradually leading to a convergence and reduction in the treatment dosing range across ailments. Table 2 presents the optimal RT doses/dose ranges administered in clinical practices to responsive subjects toward the end of the historical RT era. The continuation of this declining trend in RT dosing values from the late 1930s to well into the 1940s without an apparent leveling off suggests that the doses used in the treatment of inflammatory ailments may still not have been optimized. This view is consistent with extensive data from animal studies showing that optimized X-ray-induced anti-inflammatory phenotypes were induced with approximately 0.5 Gy.^{23,24} More recent studies have reported an accelerated healing of bone fractures with single doses (0.5 Gy) of X-rays in male Sprague-Dawley rats.³² Similarly, Jabbari et al.³³ reported that a single dose of γ -rays (0.75 Gy) immediately after surgery significantly accelerated the healing process for a full-thickness wound in male Sprague-Dawley rats. Supporting this possibility was

an experimental study by Kataoka et al.³⁴ in which a single 0.25 Gy exposure significantly enhanced liver catalase activity in adult mice 24 h after exposure. These diverse findings raise the question of whether lowering the doses and/or reducing the number of treatments could improve the healing response and, thus, the efficacy of treatment.

Clinicians, however, were sensitive to the possibility that any defined dose of RT might not only elicit varying therapeutic efficacies among different patients (depending on their genetic variability as well as developmental and age-related differences) but might also elevate risks of cancer. For example, for safety reasons clinicians tended to further reduce exposures to children¹³ while still reporting successful treatment outcomes. In further support of the efficacy and safety of lower doses, recent human studies showed that simulating cumulative radon spa exposures over about 5 months (with a 40-min duration plus a radio-nebulizer exposure) was equivalent to a dose rate of approximately 0.005 mSv/day and could significantly alleviate symptoms of rheumatoid arthritis.²⁰ This represents a total cumulative RT dose that approximates the optimal dose given at one time in the cited historical studies. These observations further suggest that optimal dosing could be achieved at still lower doses/dose rates for adults.

The above findings are consistent with the reports of Seegenschmiedt et al.^{35,36} showing that RT treatment of shoulder pain and bursitis in Germany today is quantitatively comparable to the treatment of similar ailments in the historical literature. However, most of the ailments in the present review of the historical literature are not currently being treated with RT in Germany. These ailments include gas gangrene, sinusitis, otitis media, cervical adenitis, mastoiditis, pneumonia, bronchial asthma, carbuncles, and furuncles. Thus, only in the clinical treatment of shoulder tendonitis and bursitis does the historical clinical literature reviewed herein overlap with RT treatment in contemporary Germany.

Based on these findings, a RT dose ranging between 0.3 Gy and 1.0 Gy is likely to produce an anti-inflammatory phenotype that can reduce inflammation and pain as well as promote healing. The inter-individual variation, however, that inherently characterizes a response to any given treatment dose of RT remains an issue. If one treatment dose fails to elicit adequate relief, then the degree of interindividual variation may affect the decision both to administer another treatment dose and to determine its size.

Furthermore, it would be neither unexpected nor surprising if a certain proportion of patients, due to inter-individual variation, were nonresponsive, even after several treatments. The heterogeneity of the human population would suggest that a broad therapeutic window exists for RT and that the determination of an optimal treatment dose for each individual may be challenging.

Another important consideration regarding the clinical application, dosing, and efficacy of RT is the duration or time of relief from pain and inflammation following treatment. RT studies from the historical literature on the treatment of bronchial asthma and bursitis/tendonitis¹¹ explicitly address the duration of relief. In the case of bronchial asthma, the duration of relief displayed considerable interindividual variation but was typically in the period from 1 year to 2.5 years.³⁷ These findings by Scott³⁷ were similar to the earlier results of Schilling³⁸ who found that 25% of patients remained free of asthma symptoms more than 2 years after treatment. Maytum and Leddy³⁹ reported similar findings with patients that were followed for 16 months. In the case of Hull et al.,⁴⁰ almost all patients (over 90%) were nearly completely relieved of symptoms 18 months after treatment. When the study by Hull et al. was expanded to include more than 1500 patients, it essentially replicated the success of the original study. In another study by Waldbott,⁴¹ similar findings were reported in patients who were followed out to 3 years (twice as long as Hull's study). Together, these findings lend support to the premise that limited treatment with RT can result in prolonged periods of relief, lasting many months to several years in the case of bronchial asthma. Furthermore, the interindividual variations appear to be considerable and the differences in treatment protocols appear to affect the total dose delivered per patient as well as the efficacy and, ultimately, the success of the treatment.

The duration and efficacy of RT in the treatment of bursitis and tendonitis were investigated in six studies that included more than 600 patients whose treatment results were followed for extended periods of up to 6 years.^{29,42-46} The general consensus of these studies was that the treatment benefit was virtually permanent for the vast majority of patients and was unrelated to the acute, subacute, or chronic classification of the inflammatory condition. The observation that RT can frequently induce nearly permanent cures of serious inflammatory conditions raises important theoretical

and practical questions with broad medical and public health implications.

Evidence mined from the historical literature and presented in this study indicates that relatively low doses of radiation can suppress inflammation and essentially "cure" many ailments whose underlying etiologies possess strong inflammatory components. Data from this study suggest that macrophages are polarized more toward M2 and the anti-inflammatory state when doses descend below 1.0 Gy and, conversely, more toward M1 and the pro-inflammatory state when doses ascend above 1.0 Gy. Knowledge of the optimal RT dosing ranges required to modulate the polarization of M1 and M2 phenotypes in patients could enable the clinical induction and regulation of pro- and anti-inflammatory immune states for the targeting, treating, and curing of a variety of inflammatory, infectious, and tumorigenic diseases (Figure 1).

It has been suggested that macrophages do not really exist as 100% pure M1 or M2 phenotypes but rather as varying mixes of M1 and M2 phenotypes at both the single cell and cell population levels.^{1,47} Because radiation-induced polarization induces changes in the M1 and M2 phenotypes, the "phenotypic potential" for M1 and M2 to mediate pro- and anti-inflammatory states would also change accordingly. The identification by flow cytometry, for example, of one or more molecular biomarkers that are specific to the expression of M1 and M2 responses may possibly serve as qualitative and quantitative measures of M1 and M2 "phenotypic potential." Assuming that it was possible to measure the "phenotypic potential" of M1 and M2 for individual macrophages in a cell population, it would then be possible to electronically calculate the aggregate "phenotypic potential" for the entire cell population, that is, total M1 ($M1_T$) and total M2 ($M2_T$). The "phenotypic potential" having the larger value ($M1_T$ or $M2_T$) would qualitatively denote the overall "phenotypic potential" (M1 or M2) of the cell population, while the numeric difference between total "phenotypic potentials" ($M1_T - M2_T$ or $M2_T - M1_T$) would be a quantitative measure of the net "phenotypic potential" of the entire cell population. Theoretically, data from such an experimental approach would be important because it could be used to predict and modulate, for any given dose of RT, the type and intensity of inflammatory response, that is, pro-inflammatory (M1) or anti-inflammatory (M2). The predictive and modulatory aspects of such an

experimental approach for optimal dose determination may have valuable clinical appeal.

All of the ailments considered in this study have a significant inflammatory component and should benefit preferentially from doses of radiation that polarize macrophages to an M2-like anti-inflammatory phenotype, that is, at less than 1.0 Gy. However, many of the ailments cited in this study, such as pertussis, gangrene, pneumonia, otitis media, and sinus infection, may also include an infectious component that would benefit preferentially from doses of radiation that polarize macrophages to an M1-like pro-inflammatory phenotype, that is, at more than 1.0 Gy. In such an instance where both inflammation and infection are present to varying degrees, benefits may be derived from doses either above (i.e. to treat infection) or below (i.e. to treat inflammation) 1.0 Gy. The assumption here is that both pro- and anti-inflammatory activities are induced simultaneously to promote unequally microbial killing (M1) and tissue healing (M2), depending on the dose being above or below 1.0 Gy, respectively. The historical trend toward lower doses producing the most effective treatments for inflammation suggests that inflammation can have a dominant effect on patient perceptions of health and wellness following therapy.

During the period of the 1920s to 1940s, the assessment of cancer risk for RT treatments of the various ailments reviewed in this study was not discussed. In his retrospective historical review of successful RT treatments of bronchial asthma, Waldbott⁴⁸ stated that despite high rates of clinical success he “relinquished this treatment, however, because of the possibility of long-term adverse effects.” Webber⁴⁹ provided a similar perspective and raised the issue that children who were administered RT to treat pertussis may experience an increased cancer risk. Webber⁴⁹ noted that “it is generally unappreciated by physicians that during the two decades from 1920-1940, hundreds of children received potential carcinogenic doses of radiation therapy to the thorax for whooping cough” (see p. 449). Webber⁴⁹ then concluded by raising the issue that as of the 1970s hundreds of adults may have a potentially enhanced risk of thyroid cancer due to radiation treatments for pertussis during infancy.

Since the use of RT for the treatment of benign diseases is commonly employed in Germany, the question of cancer risks due to treatment has been the object of considerable discussion since the early 1990s.^{16,50} Trott and Kamprad¹⁷ argued that the effective dose method of the International Commission of

Radiation Protection (ICRP) to estimate risk to the general population from occupational or environmental low-dose radiation exposure was not adequate for estimating the risk of cancer induction by the RT of malignant or nonmalignant diseases. This judgment was based on findings that the types of second cancers following RT are different from those caused by low-dose total-body irradiation as reported for Japanese A-bomb survivors. These RT researchers claimed that cancer risk due to the RT of benign diseases therefore should be empirically based on epidemiologic data from studies of patients who have received RT for nonmalignant diseases in the past. They further claimed that RT-induced tumors do not follow the linear non-threshold (LNT) model as used in radiation protection risk assessment.⁵¹ In most cases, they claimed that cancer risks estimated by the standard LNT method overestimated the true risks by one order of magnitude.

Ottolenghi et al.⁵¹ indicated that the most significant factor affecting cancer risk is the site of treatment. They noted that for all peripheral area treatments, such as Dupuytren’s contracture, tennis elbow, or heel spur, radiation cancer risks are very low and similar to those from common diagnostic X-ray examinations. However, for treatments of benign diseases involving sites with significant amounts of red bone marrow (i.e. head, shoulder, thorax, hip, and pelvis), the principal risk is the potential induction of leukemia. Therefore, the treatment optimization criterion should also include the reduction of the mean bone marrow dose. A recent paper by Cuttler has suggested a relatively high threshold (i.e., 500 mSv) for ionizing radiation-induced leukemia in humans, adding further debate and uncertainty to this issue.⁵²

Sautter-Bihl et al.⁵⁰ provided a quantitative estimate of cancer risk based on RT for the treatment of inflammatory joint conditions using an LNT approach. Their approach used expected average exposures that were adjusted for multiple factors, such as differential distances to the irradiated areas. The assumed exposure was 6×1 Gy dose used for joint treatments and was converted into a whole-body dose based on measured doses and a standard whole-body conversion formula. Based on this exposure and the LNT model, the authors estimated an additional 20–40 malignancies per million people over a lifetime. Since the average age of the patients was 54 years, they argued that the risks of inducing malignancies were not of any practical relevance. Their reasoning was based on the expected prolonged latency of tumor growth and their estimate of

low risk that was derived from a very conservative risk estimation method (i.e. LNT). In Germany, RT is recommended only after standard non-RT treatments have failed. Due to concerns over possible cancer risks, patients under 40 years of age would only be eligible for RT in exceptional cases and then only after being followed up with a determination of all possible risks versus expected benefits.³⁶

A final consideration concerns a potentially novel treatment option for RT. It has been reported that a protective anti-inflammatory phenotype can be induced in mice with equal efficacy when a standard X-ray dose targets a small area of inflammation (e.g. an arthritic joint) or when it is administered more broadly as a whole-body exposure.^{2,23,28–31,35} Unfortunately, this RT phenomenon is not known to have been examined in human clinical studies involving any inflammatory ailments, although such a study could have potentially significant implications. However, in the field of photobiomodulation (PBM), a similar phenomenon has been widely reported to occur in humans. Irradiation via PBM at a remote location from the site of injury has been shown to be very effective in enhancing healing and preventing tissue damage (e.g. healing skin wounds and crushed nerves as well as preventing brain and heart damage) (see Stone et al.⁵³ for a review). These findings are of considerable practical importance as they suggest that RT of an ailment located in a sensitive area (e.g. near bone marrow) could be minimized or possibly avoided. In addition, the application of RT for the treatment of degenerative neurological diseases with significant inflammatory components, such as Alzheimer's and Parkinson's disease, is now being explored^{54–59} in several case studies and a phase 1 clinical trial. Likewise, recent papers suggest the utility of RT for different types of cancers, several autoimmune diseases, and diabetes.^{19–21}

RT can be a very useful tool but, like alternative agents and technologies, its utility should be assessed within the context of other therapeutic considerations, that is, severity of ailment, alternative treatments, and patient characteristics, such as age, gender, health status, treatment risks versus benefits, among others.

Conclusions

1. The annals of medical history report that tens of thousands of patients inflicted with more than a dozen serious inflammatory ailments

during the first half of the 20th century were successfully and safely treated with low doses of radiation.

2. The dose range of therapeutic effectiveness for RT was observed to be broad, generally extending from as low as 20 r (e.g. approximate upper limit of common single computed tomography scans) to 200 r, approximately a 10-fold range. The magnitude of the beneficial response was consistently greater as the treatment dose was reduced across a spectrum of clinical conditions studied over several decades. The available data did not preclude the possibility that the efficacy of treatment might be enhanced even further at lower doses.
3. Considerable interindividual variation in response was reported, typically leading to the use of follow-up treatments for those patients not responding to a single treatment.
4. The duration of the beneficial responses to RT was assessed for bronchial asthma and bursitis and tendonitis. In each case, multiple studies reported that "relief" of symptoms extended from months to years depending on the patient. In the case of bursitis and tendonitis, several research groups considered the relief as permanent.
5. The pervasive anxiety and fear of radiation-induced cancers following the detonation of atomic bombs in 1945 as well as the proven efficacy and safety of novel antibiotics and other pharmaceuticals being developed around the same time with anti-inflammatory properties combined to elicit the rapid demise of low-dose RT.
6. Despite the near worldwide elimination of low-dose RT over 70 years ago, Germany has continued to study and use it clinically as an effective and highly valuable alternative treatment for a host of inflammatory diseases.
7. Low-dose radiation treatments are well-documented and have been proven as safe and effective; they therefore should be seriously considered as viable clinical options and studied further. The judicious application of RT by the medical community has the potential to be an effective complement to drug therapy, offering low-cost, low-risk, and often enduring relief for many symptoms of serious and potentially life-threatening inflammatory ailments.

Authors' note

The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing policies or endorsement, either expressed or implied. Sponsors had no involvement in study design, collection, analysis, interpretation, writing and decision to and where to submit for publication consideration.

Acknowledgments

EJC acknowledges longtime support from the US Air Force (AFOSR FA9550-13-1-0047) and ExxonMobil Foundation (S18200000000256).


Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

EJ Calabrese  <https://orcid.org/0000-0002-7659-412X>

References

- Calabrese EJ, Giordano JJ, Kozumbo WJ, et al. Hormesis mediates dose-sensitive shifts in macrophage activation patterns. *Pharm Res* 2018; 137: 236–249.
- Wang N, Liang H and Zen K. Molecular mechanisms that influence the macrophage M1-M2 polarization balance. *Front Immunol* 2014; 5: 614.
- Tan HY, Wang N, Li S, et al. The reactive oxygen species in macrophage polarization: reflecting its dual role in progression and treatment of human diseases. *Oxid Med Cell Longev* 2016; 2016: 2795090.
- Wu Q, Allouch A, Martins I, et al. Macrophage biology plays a central role during ionizing radiation-elicited tumor response. *Biomed J* 2017; 40: 200–211.
- Genard G, Lucas S and Michiels C. Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. *Front Immunol* 2017; 8: 828.
- Calabrese EJ. X-ray treatment of carbuncles and furuncles (boils): a historical assessment. *Hum Exper Toxicol* 2013; 32(8): 817–827.
- Calabrese EJ and Dhawan G. The role of x-rays in the treatment of gas gangrene: a historical assessment. *Dose-Response* 2012; 10: 626–643.
- Calabrese EJ and Dhawan G. How radiotherapy was historically used to treat pneumonia: Could it be useful today? *Yale J Biol Med* 2013; 86: 555–570.
- Calabrese EJ and Dhawan G. The historical use of radiotherapy in the treatment of sinus infections. *Dose-Response* 2013; 11: 469–479.
- Calabrese EJ and Dhawan G. Historical use of x-rays: treatment of inner ear infections and prevention of deafness. *Hum Exper Toxicol* 2014; 33(5): 542–553.
- Calabrese EJ, Dhawan G and Kapoor R. Use of X-rays to treat shoulder tendonitis/bursitis: a historical assessment. *Arch Toxicol* 2014; 88: 1503–1517.
- Calabrese EJ, Dhawan G and Kapoor R. The use of X rays in the treatment of bronchial asthma: a historical assessment. *Rad Res* 2015; 184: 180–192.
- Calabrese EJ, Dhawan G and Kapoor R. Radiotherapy for pertussis: an historical assessment. *Dose-Response* 2017; 2017: 1–9.
- Kahlmeter G. Roentgentherapy in rheumatic illnesses—experiment of more than ten years, from roughly 5,000 cases and more than 30,000 sessions. *Acta Radiol* 1938; 19: 529–538.
- Kuhns JG and Morrison SL. Twelve years' experience in roentgenotherapy for chronic arthritis. *New Eng J Med* 1946; 235: 399–405.
- Trott KR. Therapeutic effects of low radiation doses. *Strahlenther Onkol* 1994; 170: 1–12.
- Trott KR and Kamprad F. Estimation of cancer risks from radiotherapy of benign diseases. *Strahlenther Onkol* 2006; 8: 431–436.
- Leddy ET and Maytum CK. Roentgen treatment of bronchial asthma. *Radiology* 1949; 52(2): 199–204.
- Kojima S, Tsukimoto M, Shimura N, et al. Treatment of cancer and inflammation with low-dose ionizing radiation: three case reports. *Dose-Response* 2017; 15(1): 1–7.
- Kojima S, Tsukimoto M, Cuttler JM, et al. Recovery from rheumatoid arthritis following 15 months of therapy with low doses of ionizing radiation: a case report. *Dose-Response* 2018; 16(3): 1–7.
- Cheng J, Li FS, Wang GJ, et al. Optimal LDR to protect the kidney from diabetes: whole-body exposure to 25 mGy X-rays weekly for 8 weeks efficiently attenuates renal damage in diabetic mice. *Dose-Response* 2018; 16(3): 1–10.
- Crowe SJ and Baylor JW. The prevention of deafness. *JAMA* 1939; 112(7): 586–590.
- Calabrese EJ and Calabrese V. Reduction of arthritic symptoms by low dose radiation therapy (LD-RT) is associated with an anti-inflammatory phenotype. *Int J Rad Biol* 2013; 89(4): 278–286.

24. Calabrese EJ and Calabrese V. Low dose radiation therapy (LD-RT) is effective in the treatment of arthritis: animal model findings. *Int J Radiat Biol* 2013; 89(4): 287–294.
25. Frey B, Hehlgans S, Rodel F, et al. Modulation of inflammation by low and high doses of ionizing radiation: implications for benign and malignant diseases. *Cancer Lett* 2015; 368(2): 230–237.
26. Muller HJ. Artificial transmutation of the gene. *Science* 1927; 66(1699): 84–87.
27. Calabrese EJ. The road to linearity: why linearity at low doses became the basis for carcinogen risk assessment. *Arch Toxicol* 2009; 83(3): 203–225.
28. Belisario JC and Pugh RE. Threshold erythema dose of roentgen rays. I. Review of the literature and comment on variation of doses in use in Australia, The United States and England. *Arch Dermatol Syphilol* 1942; 45(3): 519–543.
29. Lattman I. Treatment of subacromial bursitis by roentgen irradiation. *Am J Roentgenol* 1936; 36: 55–60.
30. De Lorimier AA. Roentgen therapy in acute para-arthritis. *Am J Roentgenol Rad Ther* 1937; 38: 178–195.
31. Lattomus WW and Hunter LM. Roentgen therapy of subdeltoid bursitis. Review of 235 cases. *Delaware State Med* 1949; 21: 115–117.
32. Chen M, Huang Q, Xu W, et al. Low-dose X-ray irradiation promotes osteoblasts proliferation, differentiation and fracture healing. *PLoS One* 2014; 9(8): e104016.
33. Jabbari N, Farjah GH, Ghadimi B, et al. Acceleration of skin wound healing by low-dose indirect ionizing radiation in male rats. *Kaohs J Med Sci* 2017; 33: 385–393.
34. Kataoka T, Sakoda A, Yoshimoto M, et al. Studies on possibility for alleviation of lifestyle diseases by low-dose irradiation or radon inhalation. *Rad Prot Dosim* 2011; 146(1–3): 360–363.
35. Seegenschmiedt MH, Katalinic A, Makoski HB, et al. Radiation therapy for benign diseases: patterns of care study in Germany. *Int J Radiat Oncol Biol Phys* 2000; 47(1): 195–200.
36. Seegenschmiedt MH, Micke O, Muecke R, et al. Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines. *Br J Radiol* 2015; 88: 20150080.
37. Scott SG. Method of treating asthma by radiation. *BMJ* 1926; 1: 939–941.
38. Schilling TH. The X-ray therapy for chronic bronchitis and bronchial asthma. *Munch Med Wschr* 1910; 18: 956–960.
39. Maytum CK and Leddy E. Roentgen treatment of severe asthma. *J Allergy* 1936; 8: 66–70.
40. Hull WM, Balyeat RM and Chont LIK. The therapeutic value of roentgen treatment in chronic asthma. *Am J Roentgenol* 1943; 49: 227–233.
41. Waldbott GL. Roentgen-ray treatment of the spleen in asthma and in related allergic diseases. *Arch Intern Med* 1928; 41: 683–701.
42. Kratzman EA and Frankel RS. Roentgen therapy of peritendinitis calcarea of the shoulder. A study of 220 cases with late results. *Radiology* 1952; 59: 26–830.
43. Meginnis PJ and Lutterbeck EF. Further clinical experiences with radiation therapy in race horses. *N Am Vet* 1954; 35: 431–438.
44. Robinson D. Roentgen therapy for bursitis of the shoulder. *J Med Assoc Ga* 1950; 39: 205–209.
45. Shoss M and Otto TG. Roentgen therapy of subdeltoid tendinitis and bursitis. *Mo Med* 1955; 52: 855–863.
46. Weinberg TB. Arthritis and para-arthritis treated with the roentgen ray. Report of 161 cases. *Am J Roentgenol Rad Ther* 1940; 43: 416–424.
47. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization; nomenclature and experimental guidelines. *Immunity* 2014; 41: 14–20.
48. Waldbott GL. Asthma, then and now—Are we treating it better. *Ann Allergy* 1979; 43: 32–35.
49. Webber BM. Radiation-therapy for pertussis. Possible etiologic factor in thyroid-carcinoma. *Ann Intern Med* 1977; 86(4): 449–450.
50. Sautter-Bihl ML, Liebermeister E, Scheurig H, et al. Analgesic ionizing radiation in the management of degenerative inflammatory skeletal disease. Effectiveness and Risk. *Deuts Med Wochen* 1993; 118(14): 493–498.
51. Ottolenghi A, Smyth V and Trott KR. The risks to healthy tissues from the use of existing and emerging techniques for radiation therapy. *Rad Prot Dosim* 2011; 143(2–4): 533–535.
52. Cuttler JM. Evidence of a dose threshold for radiation-induced leukemia. *Dose-Response* 2018; 16:1–5.
53. Stone J, Mitrofanis J, Johnstone DM, et al. Acquired resilience: an evolved system of tissue protection in mammals. *Dose-Response* 2018; 2018: 1–40.
54. Cuttler JM. Response to commentary: treating Alzheimer dementia with CT-induced low-dose ionizing radiation: problematic, yet potential for more precise inquiry. *Dose-Response* 2017; 15(3): 1–3.
55. Cuttler JM, Feinendegen LE and Socol Y. Evidence that lifelong low dose rates of ionizing radiation

- increase lifespan in long- and short-lived dogs. *Dose-Response* 2017; 15(1): 1–6.
56. Cuttler JM, Moore ER, Hosfeld VD, et al. Update on a patient with Alzheimer disease treated with CT scans. *Dose-Response* 2017; 15(1): 1–2.
57. Cuttler JM, Moore ER, Hosfeld VD, et al. Second update on a patient with Alzheimer disease treated by CT scans. *Dose-Response* 2018; 16(1): 1–2.
58. Raynor S and Giordano J. Treating Alzheimer’s dementia with CT-induced low-dose ionizing radiation: problematic, yet potential for more precise inquiry. *Dose-Response* 2017; 2017: 1–4.
59. Bevelacqua JJ and Mortazavi SMJ. Alzheimer’s disease: possible mechanisms behind neurohormesis induced by exposure to low doses of ionizing radiation. *J Biomed Phys Eng* 2018; 8(2): 153–156.
60. Pinto AT, Pinto ML, Cardoso AP, et al. Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities. *Sci Rep* 2016; 6: 18765.